key: cord-0737184-slq57em1
authors: Gouin, Anna; Sberro-Soussan, Rebecca; Courivaud, Cécile; Bertrand, Dominique; Del Bello, Arnaud; Darres, Amandine; Ducloux, Didier; Legendre, Christophe; Kamar, Nassim
title: Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients
date: 2020-10-06
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2020.09.036
sha: 51b37f58c1604f2b76616d35421f355b8f003909
doc_id: 737184
cord_uid: slq57em1

INTRODUCTION: During the coronavirus disease 2019 (Covid-19) pandemic, several physicians have questioned pursuing belatacept in kidney-transplant patients in order to reduce the risk of nosocomial transmission during the monthly infusion. The effect of the conversion from belatacept to another immunosuppressive regimen is underreported. The aim of the present retrospective study was to assess the effect on kidney function and the clinical outcome of the conversion from belatacept to another regimen. METHODS: We have identified 44 maintenance kidney transplantation patients from five French kidney transplantation centers who were converted from belatacept to another regimen either because of a complication (n = 28) or another reason (patients’ request or belatacept shortage, n = 13). The follow-up after the conversion from belatacept was 27.5 ± 25.3 months. RESULTS: Overall, mean estimated glomerular filtration rate (eGFR) decreased from 44.2 ± 16 ml/min per 1.73 m(2) at conversion from belatacept to 35.7 ± 18.4 ml/min per 1.73 m(2) at last follow-up (P = 0.0002). eGFR significantly decreased in patients who had been given belatacept at transplantation as well as in those who had been converted to belatacept earlier. The decrease was less significant in patients who had stopped belatacept without having experienced any complications. Finally, eGFR decreased more severely in patients who were converted to calcineurin inhibitors (CNIs), compared to those who received mammalian target of rapamycin inhibitor (mTORi). Few patients also developed diabetes and hypertension. CONCLUSIONS: Thus, transplantation physicians should avoid stopping belatacept when not clinically required.

A lthough CNI-based immunosuppression has dramatically improved the outcome of kidney transplantation, its use is responsible for nephrotoxicity and increased risk for tumoral proliferation. This has prompted transplantation physicians to try using CNI-free regimens. An mTORi CNI-free regimen was used in de novo and maintenance kidney transplantation patients. [1] [2] [3] It was associated with significantly improved kidney function in patients who tolerated this therapy compared to those who remained on CNI-based therapy. [1] [2] [3] However, mTOR inhibitor CNIfree regimens were associated with an increased risk of occurrence of acute rejection and de novo donorspecific anti-human leukocyte antibodies (DSAs). [4] [5] [6] Thus, they are now rarely used. Conversely, CNIavoiding regimens based on the use of belatacept were confirmed to be effective in preventing acute rejection and safe after kidney transplantation. 7, 8 In de novo kidney transplantation patients, long-term use of belatacept was associated with better kidney function and an increase in patient and graft survivals compared to patients who were given cyclosporin Abased immunosuppression. 9 In maintenance kidney transplantation patients, several studies, including a phase II trial and a large retrospective real-life study, have shown that the conversion from CNI to belatacept leads to an improvement in kidney function. 10, 11 To our knowledge, the effect on kidney function and the clinical outcome of the conversion from belatacept to another regimen has not been assessed. Thus, this was the aim of the present retrospective study.

We have identified 44 maintenance kidney transplantation patients from five French kidney transplantation centers who were converted from belatacept: Besançon University Hospital (n ¼ 10), Necker University Hospital (Paris, France) (n ¼ 15), Rouen University Hospital (n ¼ 1), and Toulouse University Hospital (France) (n ¼ 18). Conversion was conducted between December 2006 and June 2018. The 44 patients had been given belatacept þ mycophenolic acid (MPA) þ steroids (S) (n ¼ 37), belatacept þ MPA (n ¼ 2), or belatacept þ mTORi S (n ¼ 5) for 14 months. Fourteen patients (31.8%) had been given de novo belatacept at transplantation, and 30 patients had been converted at 7.2 (0.6 to 223) months from CNI to belatacept for impaired kidney function and/or histology (n ¼ 29) or post-transplantation diabetes mellitus (n ¼ 1). All 14 de novo kidney transplantation patients were given belatacept þ MPA þ S. For the 30 patients who were converted to belatacept, initial immunosuppression was based on CNI þ MPA þ S (n ¼ 11

The patients' characteristics at and before conversion from belatacept to other immunosuppressive regimens are presented in Table 1 . No specific antimicrobial prophylaxis was given after conversion from belatacept.

Kidney parameters were assessed at conversion to belatacept (in the 30 patients who were converted to belatacept) 6 and 3 months before the conversion from belatacept, at conversion from belatacept, and at 3, 6, and 12 months after conversion, as well as at the last follow-up. eGFR was estimated using the abbreviated Modification of the Diet in Renal Disease formula. In all centers, DSAs were assessed yearly or in case of impaired kidney function and/or increased proteinuria. Efficacy and safety parameters were assessed after the conversion from belatacept until last follow-up (i.e., 27.5 AE 25.3 months [median 20 (6-138) months]).

According to French law (Loi Jardé), anonymous retrospective studies do not require Institutional Review Board approval. In each center, patients were identified and data were obtained from the local database, and then electronic medical records were shared by all institutions.

Reported values represent either means (AESD) or medians (ranges). Proportions were compared by the chi square test or Fisher exact test. The nonparametric Friedman test for serial measurements was used to compare quantitative variables. The Student t test was used to compare quantitative variables. A P < 0.05 was considered statistically significant.

Belatacept was stopped in 44 patients. The descriptions of baseline characteristics for all patients as well as their outcomes are presented in Supplementary Table S1. They had been given belatacept for 14 (2-137) months. Their mean age at conversion from belatacept was 57 AE 12.6 months. The reasons for stopping 

A Gouin et al.: Belatacept Cessation in Maintenance Patients belatacept are detailed in Table 2 and Supplementary  Table S1 . In 28 patients (63.6%), it was stopped because of a complication; in 13 patients, it was ceased without patients having experienced any complications; and in the last 3 patients, belatacept was interrupted because no improvement in kidney function was observed. In 34 patients, belatacept was replaced by a CNI-based regimen, and 10 patients were given an mTORi-CNI-free-based regimen. Post-conversion from belatacept immunosuppression was as follows: CNI þ MPA AE S (n ¼ 21, 47.7%), CNI þ mTORi AE S (n ¼ 7, 15.9%), CNI þ azathioprine AE S (n ¼ 3, 6.8%), CNI þ S (n ¼ 3, 6.8%), mTORi þ MPA AE S (n ¼ 8, 18.2%), and mTORi þ azathioprine AE S (n ¼ 2, 4.6%). Tacrolimus was the most commonly used CNI after belatacept cessation (94%). Its median trough level was 6 (4 to 8) ng/ml. Everolimus was the most commonly used mTORi after belatacept cessation. Its median trough level was 3 (2 to 6) ng/ml when associated with CNI and 5 (4 to 8) ng/ml when given without CNI.

Overall, in the whole population (N ¼ 44), eGFR decreased after belatacept cessation (P ¼ 0.0002 Because some patients were given belatacept at transplantation (de novo patients) whereas others were converted to belatacept mainly because of impaired kidney function and/or histology, and because in some patients belatacept was ceased due to complications that can negatively impact kidney function, we have analyzed the outcome of different subgroups of patients separately. 

Thirty patients were converted to belatacept at 7.2 (0.6 to 223) months. The mean follow-up after conversion from belatacept was 21 AE 13.1 months. eGFR decreased after belatacept was stopped (P ¼ 0.0009). Mean eGFR initially improved from 32.4 AE 13.6 ml/ min per 1.73 m 2 at conversion to belatacept to 40.8 AE 14 ml/min per 1.73 m 2 at conversion from belatacept (P ¼ 0.004). Thereafter, it decreased to 36.9 AE 18.7 ml/min per 1.73 m 2 at 12 months postconversion from belatacept (P ¼ 0.035) and 32.1 AE 17.4 ml/min per 1.73 m 2 at last follow-up (P ¼ 0.0002) (Figure 1c ).

Thirteen patients stopped belatacept because of the shortage of belatacept that occurred 3 years ago (n ¼ 5), upon their request (n ¼ 7), or because kidney function had improved after the initiation of belatacept given because of prolonged delayed graft function (n ¼ 1). The mean follow-up after conversion from belatacept was 27.9 AE 21.9 months. Overall, no significant change was observed in eGFR (P ¼ 0.3). Mean eGFR decreased from 56.4 AE 15.6 ml/min per 1.73 m 2 at conversion from belatacept to 47.7 AE 20 ml/min per 1.73 m 2 at last follow-up (P ¼ 0.07) (Figure 1d ). T-cell-mediated rejection 5

Antibody-mediated rejection 1

Mixed (Figure 2b ).

Only one patient, who was given CNI þ MPA þ S, developed a de novo DSA (2.3%) 6 months after conversion from belatacept that led to antibody-mediated rejection and graft loss. Another patient who had a DSA at conversion to belatacept developed chronic antibody-mediated rejection. A third patient experienced a T-cell-mediated rejection 16 months after conversion from belatacept. Thus, overall, 3 patients (6.8%) developed an acute rejection after belatacept cessation. Four patients (9.1%) lost their graft during follow-up: the first patient because of chronic antibody-mediated rejection, the second patient due to the development of the acute antibody-mediated rejection, the third one due to poor kidney function and severe interstitial fibrosis/tubular atrophy, and the last patient because of a cardiorenal syndrome. After the exclusion of patients who presented an acute rejection and/or a graft loss (n ¼ 5), eGFR significantly decreased in the remaining 39 patients from 46.1 AE 14.6 ml/min per 1.73 m 2 at conversion to 39.3 AE 16.2 ml/min per 1.73 m 2 at last follow-up (P ¼ 0.0002).

During follow-up, 10 patients (22.3%) experienced an infectious episode: cytomegalovirus replication (n ¼ 3), flu (n ¼ 2), norovirus infection (n ¼ 1), pneumocystis jiroveci pneumonitis (n ¼ 1), pyelonephritis (n ¼ 2), and arthritis (n ¼ 1). Eight patients (18.2%) developed de novo cancer after conversion from belatacept: 6 patients developed skin cancer 4 to 66 months after conversion form belatacept; one patient presented lung cancer 11 months after conversion from belatacept; and one patient developed an Epstein-Barr virus-positive cerebral post-transplant lymphoproliferative disease 12 months after the conversion from belatacept. Two patients (4.5%) developed de novo diabetes mellitus 1 and 3 months after belatacept cessation.

Two patients (4.5%) developed de novo hypertension 1 and 3 months after the conversion from belatacept, whereas a worsening of hypertension defined by adding antihypertension medications was observed in 10 other patients (22.7%).

Finally, 6 patients (13.6%) died during follow-up with a functioning graft. The causes for death were colon cancer (n ¼ 1), lung cancer (n ¼ 1), cerebral posttransplant lymphoproliferative disease (n ¼ 1), stroke (n ¼ 1), vascular dementia (n ¼ 1), and acute respiratory distress syndrome due to flu virus (n ¼ 1).

The effect of the conversion from belatacept to another immunosuppressive regimen is underreported. The aim of the present retrospective study was to assess the effect on kidney function and the clinical outcome of the conversion from belatacept to another regimen. Our findings were threefold: (1) the conversion from belatacept to another regimen was associated with a decrease in eGFR of w8 ml/min per 1.73 m 2 ; (2) the decrease was less significant in patients who were converted from belatacept for a reason that was not a complication, and in those who were converted to an mTORi-based CNI-free regimen; and (3) some patients developed diabetes and hypertension after conversion from belatacept.

In maintenance kidney transplantation patients, a phase II randomized controlled study showed an improvement in kidney function at 1 year in patients converted to belatacept (that was administrated with MPA and S) compared to those who were maintained on CNI (7 AE 11.99 ml/min per 1.73 m 2 ). 12 This gain was maintained at 3 years (i.e., þ1.9 ml/min per 1.73 m 2 per year). 10 In a large retrospective real-life European multicenter study that included 219 maintenance kidney transplantation patients, mean eGFR significantly increased from 32 AE 16.4 ml/min per 1.73 m 2 at conversion to belatacept to 38 AE 20 ml/min per 1.73 m 2 at 21.9 AE 20.2 months later. 11 In the present study, we observed another way that eGFR decreases by w8 ml/ min per 1.73 m 2 after conversion from belatacept. This decrease was observed in patients who had received belatacept at transplantation and in those who had been converted to belatacept earlier because of impaired kidney function and/or histology.

In nearly two-thirds of patients, belatacept was stopped because of a complication, mainly because of a viral infection. It was recently shown that cytomegalovirus infection is the main opportunistic infection observed in belatacept-treated kidney transplantation patients. 13, 14 Conversely, in 30% of patients, belatacept was stopped either at the patients' request or because of belatacept shortage. In these patients in whom belatacept was stopped without having experienced any complication, eGFR also decreased from 56.4 AE 15.6 ml/min per 1.73 m 2 at conversion from belatacept to 47.7 AE 20 ml/min per 1.73 m 2 at last follow-up (P ¼ 0.07). Because of the small number of patients, the decrease in eGFR was not statistically significant. An improvement in eGFR was observed in 7 patients after belatacept cessation. Most of them were converted because of a complication. Thus, we speculate that the improvement is related to the resolution of the complication.

The improvement in kidney function after stopping CNI was often attributed to the loss of CNI-associated intrarenal vasoconstriction. 15 In the present study, in patients converted from belatacept to CNI, eGFR decreased from 44.1 AE 15.3 ml/min per 1.73 m 2 to 34.8 AE 18.9 ml/min per 1.73 m 2 at last follow-up (P < 0.0001), whereas in those converted from belatacept to an mTORi-based CNI-free regimen, no significant change in eGFR was observed (i.e., 44.6 AE 17.4 ml/min per 1.73 m 2 at conversion from belatacept and 38.5 AE 18.3 ml/min per 1.73 m 2 at last follow-up; P ¼ 0.2). Thus, after belatacept cessation, a lesser eGFR decrease was observed in patients who stopped it without having experienced a complication and in patients who were given mTORi without CNI. Although the risk of de novo DSAs is increased in kidney transplantation patients who receive the latter combination, 4,5 several studies have shown improved kidney function in patients given an mTORi-based therapy compared to those on CNI-based immunosuppression.

The use of belatacept was associated with a decreased risk of metabolic syndrome, post-transplant diabetes mellitus, and hypertension. 16, 17 In the present study, some patients developed de novo diabetes and de novo hypertension in the first 3 months after conversion from belatacept.

There are several limitations for the present study. It is retrospective uncontrolled study that included a small number of patients. The evolution of eGFR should be interpreted with caution because in 28 of 44 patients, belatacept was stopped because of a complication that could have had a negative impact on kidney function. Finally, we acknowledge the lack of kidney allograft histology at conversion from belatacept and at last follow-up. In summary, ceasing belatacept is associated with a significant decrease in kidney function.

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation

Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen

Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)

Belatacept and longterm outcomes in kidney transplantation

Safety and efficacy outcomes 3 years after switching to belatacept from a calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial

Conversion to belatacept in maintenance kidney transplant patients: a retrospective multicenter european study

Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study

Opportunistic infections after conversion to belatacept in kidney transplantation

CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept

Cyclosporine nephropathy: pathophysiology and clinical impact

Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)

Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes

DD has received grants from Astellas and Neovii. CL has received lecture fees from Astellas, Novartis, Chiesi, CSL Behring, and Hansa Medical, and travel grants from Astellas, CSL Behring, and Alexion. NK has received lecture fees from Astellas, Novartis, Gilead, Neovii, MSD, Octapharma, and Amgen, and travel grants from Astellas, CSL Behring, Novartis, and Alexion. All the other authors declared no competing interests.

AG collected the data from Toulouse, pooled the data from all centers, and wrote the paper. RS-S and CL collected the data from Necker Hospital and reviewed the paper. CC and DD collected the data from Besançon Hospital and reviewed the paper. DB collected the data from Rouen Hospital and reviewed the paper. ADB and AD reviewed the paper. NK designed the study, did the statistical analyses, and wrote the paper.

Supplementary File (PDF) Supplementary Table S1 . Clinical course of all 44 patients who were included in the study.